These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11753551)

  • 1. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
    Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M
    Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation.
    Kiel K; Cremer FW; Rottenburger C; Kallmeyer C; Ehrbrecht E; Atzberger A; Hegenbart U; Goldschmidt H; Moos M
    Bone Marrow Transplant; 1999 May; 23(10):1019-27. PubMed ID: 10373068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma.
    Cremer FW; Ehrbrecht E; Kiel K; Benner A; Hegenbart U; Ho AD; Goldschmidt H; Moos M
    Bone Marrow Transplant; 2000 Oct; 26(8):851-8. PubMed ID: 11081384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
    Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
    Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.
    Bakkus MH; Bouko Y; Samson D; Apperley JF; Thielemans K; Van Camp B; Benner A; Goldschmidt H; Moos M; Cremer FW
    Br J Haematol; 2004 Sep; 126(5):665-74. PubMed ID: 15327517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
    Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
    Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
    Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
    Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation.
    Gemmel C; Cremer FW; Weis M; Witzens M; Moldenhauer G; Koniczek KH; Imbach U; Ho AD; Moos M; Goldschmidt H
    Ann Hematol; 2002 Feb; 81(2):119-23. PubMed ID: 11907796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield.
    Kiel K; Cremer FW; Ehrbrecht E; Wallmeier M; Hegenbart U; Goldschmidt H; Moos M
    Bone Marrow Transplant; 1998 Jun; 21(11):1109-15. PubMed ID: 9645573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor load in patients with follicular lymphoma post stem cell transplantation may correlate with clinical course.
    Chang CC; Bredeson C; Juckett M; Logan B; Keever-Taylor CA
    Bone Marrow Transplant; 2003 Aug; 32(3):287-91. PubMed ID: 12858200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.
    Martinelli G; Terragna C; Lemoli RM; Cavo M; Benni M; Motta MR; Amabile M; Ottaviani E; Testoni N; de Vivo A; Tura S
    Haematologica; 1999 May; 84(5):397-404. PubMed ID: 10329917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.
    Boccadoro M; Omedé P; Dominietto A; Palumbo A; Bringhen S; Giaretta F; Ortolano B; Triolo S; Pileri A
    Bone Marrow Transplant; 2000 Jan; 25(1):25-9. PubMed ID: 10654010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
    Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
    Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
    Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
    Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.